Is roselixizumab already covered by medical insurance?

So far, Rozanolixizumab (Rozanolixizumab) has not been included in the national medical insurance directory in mainland China, nor has it been officially sold in the country. Although the drug has been approved for marketing by the U.S. Food and Drug Administration (FDA) and has gradually entered the market in some European countries, it is still at an early stage in the Chinese market and may still be undergoing drug registration or review and approval processes.

China's national medical insurance drug catalog is usually updated once a year, and the inclusion process includes multiple links such as enterprise application, expert evaluation, technical review, and price negotiation. Novel and expensive biological agents such as roselixizumab usually require sufficient clinical use data and registration basis in China before they are eligible for medical insurance negotiations. Due to the high price of this drug and its use in the treatment of relatively niche autoimmune neurological diseases, it has not yet appeared on the public list of medical insurance negotiations or been included in the intention list.

In addition, even if roselixizumab enters the Chinese market in the future, its medical insurance coverage will not be available immediately. At present, domestic medical insurance has high access thresholds for biological drugs, and usually gives priority to drugs with urgent treatment needs, sufficient clinical evidence, and relatively controllable economics. Other FcRn-targeted drugs such as Efgartigimod are still in the early stages of deployment in China, so it can be speculated that the timetable for inclusion of roselixizumab in medical insurance may still take a long time.

For patients, if there is an urgent need to use roselixizumab, they need to rely on cross-border drug purchase channels, such as importing the drug through Hong Kong, European and American markets. However, because its price is relatively high and it is a professional injection drug, it needs to be professionally evaluated under the guidance of a doctor and used in a suitable medical environment to ensure safety and effectiveness.

Reference materials:https://www.drugs.com/rystiggo.html